Steven Leonard Chapman Sells 1,590 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 1,590 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $235.00, for a total value of $373,650.00. Following the transaction, the chief executive officer directly owned 219,150 shares of the company’s stock, valued at $51,500,250. This trade represents a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The shares were sold at an average price of $229.08, for a total value of $881,499.84.
• On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The stock was sold at an average price of $238.07, for a total value of $1,047,508.00.
• On Monday, November 3rd, Steven Leonard Chapman sold 160,703 shares of Natera stock. The shares were sold at an average price of $199.96, for a total value of $32,134,171.88.
• On Tuesday, October 28th, Steven Leonard Chapman sold 3,680 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $704,572.80.
• On Monday, October 27th, Steven Leonard Chapman sold 2,335 shares of Natera stock. The stock was sold at an average price of $192.32, for a total transaction of $449,067.20.

Natera Stock Down 0.5%

Shares of NASDAQ:NTRA opened at $241.58 on Friday. The company’s 50-day moving average price is $234.18 and its 200 day moving average price is $191.17. The company has a market cap of $33.42 billion, a PE ratio of -105.49 and a beta of 1.62. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. Natera’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.26) EPS. As a group, equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Hedge Funds Weigh In On Natera

A number of institutional investors have recently bought and sold shares of the stock. Flagship Harbor Advisors LLC purchased a new stake in Natera during the fourth quarter valued at about $41,000. Hilltop National Bank acquired a new stake in shares of Natera during the second quarter valued at approximately $33,000. Horizon Investments LLC acquired a new stake in shares of Natera during the third quarter valued at approximately $32,000. Sound Income Strategies LLC lifted its position in shares of Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares in the last quarter. Finally, Quent Capital LLC acquired a new position in Natera in the 3rd quarter worth approximately $46,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Peer‑reviewed clinical validation: Natera published clinical validation of its Latitude™ tissue‑free MRD test in colorectal cancer, boosting the credibility of a higher‑value oncology product that could support future revenue and reimbursement expansion. Clinical validation article
• Positive Sentiment: Analyst support: Multiple sell‑side firms have raised price targets and the consensus remains a “Moderate Buy” with an implied target around the mid‑$200s, providing medium‑term bullish backing for the stock.
• Neutral Sentiment: Fund positioning note: A Voya MidCap Opportunities investor letter and related coverage highlight that lack of exposure to Natera hurt that fund’s Q4 performance — a sign NTRA was a notable outperformer for some mid‑cap portfolios but not a direct company catalyst. Voya fund note
• Neutral Sentiment: Mixed fundamentals & ownership: Recent quarter showed strong revenue growth (~35% YoY) but continued GAAP losses; institutional ownership is extremely high (~99.9%), which reduces free float and can both support and cap volatility depending on flows.
• Negative Sentiment: Clustered insider selling — material: CEO Steven Chapman, CFO Michael Burkes Brophy and other insiders executed large sales on Jan. 20–21 (CEO sale ~71.9k shares; CFO sales totaling ~61k+ shares across days), representing sizable reductions in holdings and increasing perceived near‑term supply pressure. CEO Form 4
• Negative Sentiment: Additional insider sales: Multiple smaller insider transactions (e.g., Solomon Moshkevich) were also reported, reinforcing the market perception of insider liquidity taking and adding downward pressure. InsiderTrades coverage

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on NTRA shares. Stephens increased their price target on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Guggenheim raised their target price on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, January 5th. UBS Group boosted their price target on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Wells Fargo & Company increased their price objective on shares of Natera from $190.00 to $205.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $245.50.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.